Menopause

Bayer's elinzanetant, a potential nonhormonal treatment for menopausal symptoms, awaits FDA approval after a 90-day review extension.

Low sexual desire affects up to 40% of women across the lifespan but currently there is no treatment option for those beyond their reproductive years.

Experts reviewed data from the 2002 Women's Health Initiative study that prompted class warnings for estrogen-containing therapies and called for changes, education.

Combined estrogen-progestin hormone therapy used to manage VMS of menopause was associated with a higher risk of developing luminal-like breast cancer subtypes and other subtypes.

Key predictors of the severity of self-reported cognitive complaints among nurses going through menopause included symptom severity and climacteric stage.

Bayer's elinzanetant gains UK approval as the first dual-action, nonhormonal treatment for menopausal symptoms.

Social determinants including partner status, smoking history, and BMI were significantly associated with reduced access to effective hormone therapy for menopausal women.

ASCO 2025. Elinzanetant significantly reduced the frequency of VMS vs placebo in women on endocrine therapy for treatment or prevention of HR+ breast cancer.

Details on 12 key abstracts with clinical relevance for primary care, from menopause management to PPD screening and HPV testing.

Elinzanetant reduced VMS frequency and intensity, and improved sleep and quality of life, according to the meta-analysis to be presented at the ACOG 2025 meeting.